Clinical trials: Relapsed/Refractory B-Cell Neoplasms
Diffuse Large B-Cell Lymphoma (DLBCL)
Study to Evaluate the Feasibility and Safety of Autologous Cytokine-Induced Killer Cells (CIK_D332) in Combination With Tafasitamab and Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
This is a multicentre, Phase I trial of Cytokine Induced Killer-cells (CIK_D332) in combination with Tafasitamab and Lenalidomide in patients with Diffuse Large B-cell Lymphoma (DLBCL) who have relapsed or are refractory after at…
- Trial name
- FOCUS (NCT07906080)
- Testing
- The treatment regimen consists of a combination of Tafasitamab, Lenalidomide, and CIK_D332
- Where
- 2 sites in Italy
- Volunteers
- 14 people
- Sponsor
- Istituto Oncologico Veneto IRCCS
Hematologic Malignancies, Solid Tumor
A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors
Multicenter, open-label, phase 1a/1b trial of PF-07901800 (TTI-621) in subjects with relapsed or refractory hematologic malignancies and selected solid tumors.
- Trial name
- NCT02663518
- Testing
- PF-0791800 (TTI-621), PF-07901800 (TTI-621) plus Rituximab, PF-07901800 (TTI-621) plus Nivolumab
- Where
- 51 sites in United States, Canada
- Volunteers
- 249 people
- Sponsor
- Pfizer
Leukemia, Lymphoma
Donor Lymphocyte Infusion in Treating Patients With Recurrent or Persistent Hematologic Cancer After Donor Stem Cell Transplant
RATIONALE: Giving an infusion of donor lymphocytes may be able to kill cancer cells in patients with hematologic cancer that has come back after a donor stem cell transplant.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00534118
- Testing
- donor lymphocytes
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Roswell Park Cancer Institute
Non-hodgkin Lymphoma,B Cell
The Safety and Efficacy of Double-target CART-19 and 20 Cells in Non-Hodgkin's Lymphoma (NHL)
This is a study for patients who have been previously treated for NHL. The purpose of this study is to determine the safety and feasibility of double-target CART-19 and 20 cells to the patients with relapsed and refractory…
- Trial name
- NCT06160362
- Testing
- CART-19 and 20 cells, Cyclophosphamide, Fludarabine
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Henan Cancer Hospital
Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma
A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)
The primary objective of this study is to determine the recommended dosing regimen of loncastuximab tesirine in diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBCL) participants with moderate and severe…
- Trial name
- NCT05660395
- Testing
- Loncastuximab Tesirine
- Where
- 14 sites in United States, Brazil and 2 more
- Volunteers
- 5 people
- Sponsor
- ADC Therapeutics S.A.
Leukemia, Lymphoma
Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease
RATIONALE: When irradiated lymphocytes from a donor are infused into the patient they may help the patient's immune system kill cancer cells. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00176475
- Testing
- rituximab, therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Perifosine inhibits the AKT pathway (a way cells communicate with each other). This pathway is felt to be important in the development of several types of cancers including chronic lymphocytic leukemia (CLL) or small lymphocytic…
- Trial name
- NCT00873457
- Testing
- perifosine
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Daphne Friedman
Chronic Lymphocytic Leukemia, Leukemia, B-Cell, Chronic
A Dose Escalation Study of Lenalidomide in Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia
The purpose of this study is to evaluate the safety of lenalidomide and to define the maximum tolerated escalation dose level (MTEDL) when administered by a stepwise dose-escalation schedule in subjects with relapsed or…
- Trial name
- NCT00419250
- Testing
- lenalidomide
- Where
- 35 sites in United States, Canada and 5 more
- Volunteers
- 52 people
- Sponsor
- Celgene
Hematopoietic Cell Transplantation Recipient, Recurrent Diffuse Large B-Cell Lymphoma
Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma
This phase I/II trial studies the side effects and best dose of venetoclax when given together with carmustine, etoposide, cytarabine, and melphalan before stem cell transplant in treating participants with non-Hodgkin lymphoma…
- Conditions
- Hematopoietic Cell Transplantation Recipient, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma
- Trial name
- NCT03583424
- Testing
- Carmustine, Cytarabine, Etoposide
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Ohio State University Comprehensive Cancer Center
Diffuse Large B Cell Lymphoma, Relapse/Recurrence
Decitabine and Anti-PD-1 in R/R DLBCL
Patients with relapsed/refractory diffuse large B cell lymphoma with extranodal (esp. central nervous system) involvement treated with Low-Dose Decitabine plus anti-PD-1 regimen.
- Conditions
- Diffuse Large B Cell Lymphoma, Relapse/Recurrence, Extranodal Extension, Central Nervous System Lymphoma
- Trial name
- NCT05816746
- Testing
- Low-Dose Decitabine plus anti-PD-1
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Chinese PLA General Hospital
Multiple Myeloma, Refractory, Diffuse Large B-Cell Lymphoma
A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma
This study will include participants with relapsed/refractory (R/R) Multiple Myeloma (MM). MM is a type of cancer of the blood. This study will also include participants with relapsed/refractory (R/R) Diffuse Large B-Cell…
- Conditions
- Multiple Myeloma, Refractory, Diffuse Large B-Cell Lymphoma, Diffuse Large B Cell Lymphoma Refractory, Multiple Myeloma in Relapse
- Trial name
- NCT05121103
- Testing
- EZM0414
- Where
- 8 sites in United States
- Volunteers
- 13 people
- Sponsor
- Epizyme, Inc.
Follicular Lymphoma, Lymphoma, Large B-Cell, Diffuse
A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
This Phase Ib/II, open-label, multicenter, non-randomized, dose-escalation study will evaluate the safety, efficacy, and pharmacokinetics of obinutuzumab in combination with idasanutlin and venetoclax in participants with R/R FL…
- Trial name
- NCT03135262
- Testing
- Idasanutlin, Obinutuzumab, Venetoclax
- Where
- 21 sites in United States, Australia and 3 more
- Volunteers
- 29 people
- Sponsor
- Hoffmann-La Roche
B Cell Lymphoma
BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma
In this single-center, single-arm, prospective, Phase 1/2 study, the safety and efficacy of autologous BCOR and ZC3H12 genes knock-out CD19-targeting chimeric antigen receptor (CAR) T-cell therapy will be evaluated in patients…
- Trial name
- NCT07009002
- Testing
- CAR19TIF cells, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chinese PLA General Hospital
Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia
Palbociclib and Dexamethasone in Treating Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
This phase I trial studies the side effects and best dose of palbociclib when given together with dexamethasone in treating participants with B-cell acute lymphoblastic leukemia that has come back after a period of improvement or…
- Trial name
- NCT03472573
- Testing
- Palbociclib, Dexamethasone
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Follicular Lymphoma, Diffuse Large Cell Lymphoma
Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies
This is an open-label, multicenter, phase II study to evaluate the safety and efficacy of single-agent AT-101 in patients with relapsed or refractory B-cell malignancies.
- Conditions
- Follicular Lymphoma, Diffuse Large Cell Lymphoma, Mantle Cell Lymphoma, Small Lymphocytic Lymphoma
- Trial name
- NCT00275431
- Testing
- AT-101
- Where
- 11 sites in United States
- Volunteers
- 50 people
- Sponsor
- Ascenta Therapeutics
Lymphoma, B-Cell, Marginal Zone
Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Marginal Zone Lymphoma
The purpose of this study is to assess the efficacy and safety of Ibrutinib in predominantly Asian patients with relapsed or refractory marginal zone lymphoma.
- Trial name
- NCT03093831
- Testing
- Ibrutinib
- Where
- 2 sites in Singapore
- Volunteers
- 5 people
- Sponsor
- National Cancer Centre, Singapore
Relapsed, Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05)
This study is a phase 1, dose finding, open-label study in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
- Trial name
- NCT02658968
- Testing
- Betalutin
- Where
- 10 sites in United States, Germany and 3 more
- Volunteers
- 18 people
- Sponsor
- Nordic Nanovector
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant
RATIONALE: Rasburicase may be an effective treatment for graft-versus-host disease caused by a donor stem cell transplant. PURPOSE: This clinical trial is studying how well rasburicase works in preventing graft-versus-host…
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00513474
- Testing
- busulfan, cyclophosphamide, cyclosporin-A
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Massachusetts General Hospital
B-Cell Lymphoma Stage I, Refractory
CD19/20 Bispecific Nanobody-derived CAR-T Cells in B Cell Lymphoma
Evaluation the safety and efficacy of CD19/CD20 bispecific CAR-T cells in patients with relapsed/refractory B cell lymphoma
- Conditions
- B-Cell Lymphoma Stage I, Refractory, Relapsed
- Trial name
- NCT03881761
- Testing
- CD19/CD20 bispecific CAR-T cells
- Where
- 2 sites in China
- Volunteers
- 50 people
- Sponsor
- Henan Cancer Hospital
B-cell Non Hodgkin Lymphoma
A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- NHL
The study is an early, open, single-centered trial. The aim of this study is to evaluate the safety and tolerance of GC022F CAR-T cell immunotherapy in relapsed or refractory B-NHL.
- Trial name
- NCT04412174
- Testing
- GC022F
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Hebei Yanda Ludaopei Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.